Montag, 26. Juli 2021
Navigation öffnen

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer



November 2019

Letztes Update:

intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)

Indikation (Clinical Trials):
Stomach Neoplasms


Erwachsene (18+)

Phase 2

University Hospital Tuebingen



Alfred Königsrainer, MD
Phone: +49-7071-29-
Phone (ext.): 86620
» Kontaktdaten anzeigen

(1 von 1)

University Department of General, Visceral and Transplant Surgery
72076 Tuebingen
GermanyRekrutierend» Google-Maps
Alfred Königsrainer, MD
Phone: +49-7071-29
Phone (ext.): -86620
» Ansprechpartner anzeigen


Detailed Description:

An operation and the constant further development of the surgical techniques can not always prevent the recurrence of a tumor of the stomach or the transition from the esophagus to the stomach. As reason for this recurrence, the investigators assume that the tumor was already present at the time of the surgery and has crossed the boundaries of the stomach or free tumor cells are located in the peritoneal cavity, even if they can't be found with the bare eye or imaging methods. Such free tumor cells have the possibility of developing metastases within the abdominal cavity.

An innovative local treatment method is being tested in Tübingen and applied to remove any remaining free tumor cells or very small and invisible residual tumors. These free tumor cells can be determined prior to the start of treatment by peritoneal endoscopy (diagnostic laparoscopy). If these can be identified by lavage of the abdominal cavity there is an increased risk for the development of peritoneal metastases. Therefore, in patients with detected free tumor cells in the lavage water of the abdominal cavity, after the removal of the stomach, should be used once a chemotherapy in the abdominal cavity, which is warmer than the body (intraoperative hyperthermic chemotherapy, HIPEC). In this study the investigators want to demonstrate, that the single administration of intraoperative HIPEC with cisplatin and doxorubicin in addition to routine surgery delays the onset of peritoneal metastases and the additional therapy with its low risks is reasonable.


Inclusion Criteria:

- Written informed consent of the patient

- Positive lavage cytology in staging laparoscopy

- Intraoperative R0- or R1-gastrectomy (Re-evaluation intraoperative)

- Histologically confirmed locally advanced, resectable Adenocarcinomas of the stomach (incl. AEG II-III): >cT3 and/or cN+ and cM0 (none existing solid Peritoneal metastases, Re-evaluation intraoperative)

- Neoadjuvant chemotherapy ≥ 2 cycles

Exclusion Criteria:

- < 18 years

- Existence of contraindications or contraindications against the study medication

- Uncompensated Heart Failure (NYHA III and IV)

- Severe CHD, medically insufficient treatable cardiac arrhythmias, uncontrolled arterial hypertension

- Serum creatinine ≥ 1.5 x the standard value or a Creatinine clearance < 60 ml/min/1.73 m2

- Severe pulmonary dysfunction (COPD, PAH), Pulmonary function test confirmed (IVC < 55 %, DLCO < 40%)

- malignant secondary tumor disease that persists for < 5 years (Exception: in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin)

- Participation in other interventional studies that at the time of the ProPeC study inclusion, still are not finished

- pregnancy or lactation


Primary outcome:

1. Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC. (Time Frame - one year):
The primary objective of the study is to estimate the effect of a combined therapy with gastrectomy and HIPEC in localized advanced gastric cancer. The primary target is the incidence of peritoneal metastases in CT and the proportion of patients who after one year are free from peritoneal metastasis. The study is intended to provide planning data for a subsequent Phase III study in the form of an RCT.

Secondary outcome:

1. Overall Survival (OS) (Time Frame - one year):
Overall Survival (OS) measured in years.

2. Progression-free survival (PFS) (Time Frame - one year):
Progression-free survival (PFS) based on imaging (CT).

3. Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo. (Time Frame - one year):
Expected adverse events (AEs) of particular interest must be recorded from grade ≥ III according to CTCAE v5.0 or postoperative complications according to Clavien-Dindo classification from grade ≥ 3b by AE/ADR reporting. Unexpected and expected AEs must be documented and reported as SAE from grade IV according to CTCAE v5.0 or from grade 4-5 according to Clavien-Dindo classification.

Geprüfte Regime

  • intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC):
    single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy


Das könnte Sie auch interessieren
Onkologie 20.02.2012

Selbsthilfe bei Lungenkrebs: Betroffene helfen Betroffenen

EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose